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1INTRODUCTION
Incidence of Gastric Cancer
Stomach cancer is the 2nd most common cause of cancer related
mortality in both men and women aged 30–69 years in India next only to
oral cancer in men and cervical cancer in female. 1
Worldwide, stomach cancer is the 2nd leading cause of cancer death
and 4th most common cancer type. Gastric cancer is more common in East
Asia and South America than other parts of the world. Gastric cancer is
increasing in developing countries and the rates have been decreasing in
the developed countries. Among developed countries, Korea and Japan
have the highest rates of incidence. But, the mortality rate has dropped by
50% in the above countries as a result of the screening programme. Distal
stomach is the most common site in developing countries and in Japan.
Incidence and Mortality Trends
Worldwide, stomach cancer was the most common cause of cancer-
related death. But, the rates have started to decline. The mortality rate has
halved in Europe and Russia. This fall is less pronounced in developing
than in developed countries. 2
This fall in stomach cancer rates are because of the following:
21. More affluent diet, with increased consumption of fresh fruits
2. Better food preservation, including refrigeration
3. Effective treatment of Helicobacter pylori infection
4. Decrease in smoking
Trends in Gastric cancer by site and histology
The gastric cancer incidence is declining mainly due to the decrease
in the incidence of intestinal type cancers but, the incidence of diffuse type
cancers has been generally stable throughout the world.
Also, the cancers arising from the gastric body and antrum are
decreasing and the proximal gastric cancers are increasing.
Risk factors for gastric cancer
Advancing age
Advancing age is a risk factor for cancer stomach. The number of
cases increases with age. Most deaths occur in the 50-70 age group. The
increasing frequency of stomach cancer is due to the accumulation somatic
mutations with age.
3Sex
Stomach cancer is 2 times more common in men than women. 70%
of gastric cancer patients are men and only 30% are women.
Obesity
Obesity results in a 2 times more risk of malignancy of cardia of
stomach in comparison to non-obese people. 9
Diet
Excessive salt, excessive consumption of fish and other seafood is
an etiology for gastric cancer.  Reduced consumption of vegetables and
fresh fruits also plays an important role in etiology. Improvements in food
processing and storage and refrigeration have significantly decreased the
incidence of gastric cancers worldwide. High red meat consumption is also
implicated as an etiological factor for gastric cancer.
The mechanism of carcinogenesis is the conversion of nitrates in the
food to carcinogenic N-nitroso compounds in the stomach. This chemical
change leads to decreased mismatch repair (MMR) genes activity and
increased tolerance to DNA damage thereby resulting in the errors of DNA
strands.
4Antioxidants in fruits like the ascorbic acid, catechins and
tacopherols remove the mutagenic N-nitroso compounds and oxygen free
radicals, thereby having anti-cancer effect. Microelements like zinc,
selenium and magnesium also have a protective effect. 3
Helicobacter pylori Infection
Infection of the mucosa of the gastric wall with Helicobacter pylori
(H. pylori) leads to acid peptic disease and in the long run, malignancy. H.
pylori is designated as a class I carcinogen by the World Health
Organization. There is a 7 times increased risk of stomach cancer in H.
pylori infected individuals.
The exact mechanism of carcinogenesis is not completely
understood. H. pylori with VacA (valulocating cytotoxin A) and cagA
(cytotoxin associated gene A) genes induce a more severe infection. The
cytotoxin produced by these genes increases the virulence. Cag A
positivity increases the risk of cancer by intensifying the immunological
response, and by stimulating the release of IL-8, a chemokine which
damages the mucosa. Also, a large amount of urease is produced by H.
pylori, which break the urea into carbon dioxide and ammonia. The latter,
neutralizes the hydrochloric acid thereby producing a increased pH
environment enabling the bacterial growth in the gastric wall.
5H. pylori induced inflammation results in increase of free radicals
and cellular DNA damage thereby increasing the risk of cancer. H. pylori
also stimulates the production of an array of inflammatory interleukins and
Chemokines which further stimulate the immunological processes and
chronic inflammation, paving the way for cancer development.
The molecular alterations described in intestinal metaplasia include
overexpression of COX-2 and cyclin D2, low p27 expression, p53
mutations, transcription factors alteration including the CDX1 and CDX2,
and microsatellite instability.
H. pylori cause cancer by the following mechanisms:
1. Metabolic products affecting the stomach mucosa directly
or
2. Indirectly by increasing the DNA damage risk, thereby
making the mucosa susceptible to malignant change by
carcinogens and by-products of infection.
Furthermore, eradication of H. pylori reduces the cancer risk in
patients below the age of 40 years. Also, H. pylori status is a significant
prognostic factor and negative H. pylori status is an indicator of poor
prognosis in patients with gastric cancer.
6Epstein-Barr virus (EBV) infection
Epstein-Barr virus infection is present in nearly 15% of stomach
cancer subjects. EBV associated gastric carcinoma is non-endemic and has
distinct characteristics like more diffuse type tumors,  increased incidence
of body and fundal tumors and predominance in males. The characteristic
molecular abnormality is the promoter area methylation of the malignant
genes. But, EBV associated stomach cancer has a better outlook compared
to the negative tumors.
Mechanisms of EBVaGC include:
• DNA methylation
• Viral small RNAs
• Epigenetic alterations and
• Altered microRNAs expression of the host cells
Alcohol and Smoking
The duration and the frequency of smoking parallels the stomach
cancer risk. Consuming alcohol greater than five occasions in two weeks
and smoking more than 20 cigarettes per day increases the risk of stomach
7cancer 5 fold. Also, there is an increased risk for passive smokers
compared to those who don’t smoker. 10
Carcinogens contained in cigarette smoke include tar, polycyclic
hydrocarbons and N-nitroso compounds. Carcinogens form covalent bonds
with DNA, altering their function and pave the way for stomach cancer.
Alcohol ingestion also, significantly increases the risk of developing
gastric cancer. Consumption of 4 or more drinks a day significantly
increases the risk of developing gastric cancer.
Alcohol stimulates gastric motility and gastric juice production.
Ethanol causes mucous membrane damage by reducing the blood flow,
decreased mucus production, increase in pro-inflammatory cytokines, and
causing oxidative stress. Also, the vodka and other alcoholic beverages
contain nitrosamines that accentuate the risk of stomach cancer.
Socioeconomic status
Persons belonging to the lower socioeconomic status have an
increased risk of developing the stomach cancer. Professions which have
an exposure to nitrates and/or herbicides during work, also have an
increased risk of developing the gastric cancer.
8Migration
Reduction in the incidence of cancer is observed when migrating
from a high risk area to a low risk area. For example, Japanese born in the
United States have a low occurrence of gastric cancer similar to US
population in comparison to recent immigrants.
Hereditary Risk Factors
Gastric cancer is associated with many rare inherited disorders that
include:
1. Hereditary Diffuse Gastric Cancer
2. Familial Adenomatous Polyposis
3. Hereditary Nonpolyposis Colorectal Cancer
4. Li-Fraumeni syndrome
Hereditary Diffuse Gastric Cancer
Sporadic stomach cancers account for the majority of stomach
cancer cases. But, in about 12% of gastric cancer cases, familial clustering
is seen. About 2% of the familial clustering cases have the hereditary
diffuse gastric cancer (HDGC).
9Germline mutation in the CDH1 gene causes the autosomal
dominant HDGC. The CDH1 gene located in chromosome 16 and encodes
a 120-kDa protein called E- cadherin. E- cadherin is present on cells of all
the epithelium and plays a crucial role in the intercellular adhesions. E-
cadherin establishes and maintains the polarity of the epithelium by the
intercellular adhesion formation and thereby it suppresses the invasiveness.
Decreased expression of E- cadherin is associated with invasiveness and
metastatic spread.
The International Gastric Cancer Linkage Consortium (IGCLC) has
laid down the criterion for diagnosis of HDGC. Families which don’t
fulfill the IGCLC criteria but have an index case are grouped into one of
the following types:
1. Familial Diffuse Gastric Cancer (FDGC) 4
2. Familial Gastric Cancer (FGC)
3. Familial Intestinal Gastric Cancer (FIGC)
Genetics of HDGC
Guilford et al. first described the genetic linkage of HDGC in 1998.
The various common CDH1 mutations include missense mutations and
insertions or deletions. But, irrespective of the type of mutation, most
10
result in a truncated protein without any function. CDH1 deregulation is an
initial event in HDGC.
CDH1 mutation subjects are found concentrated in Canada and New
Zealand. But, in Asia, where a high incidence of sporadic gastric cancer is
seen, the incidence of CDH1 mutations is very low. The reason for this is
not known.
HDGC is diagnosed at a mean age of 40 years. The lifetime risk of
developing stomach cancer is about 65% in men and 80% in women. The
penetration of CDH1 germline mutation in HDGC is very high. The
presence of a CDH1 mutation is also associated with increased risk of
lobular  breast  cancer  among  women.  This  high  penetrance  of  CDH1
mutation highlights the importance of identifying the carriers and the early
diagnosis of HDGC which may translate to better prognosis and longer
survival rates in these patients. 6
Recommendations for CDH1 screening:
 The IGCLC published the recommendations for CDH1 testing in
1999. Shortly after, many other revised guidelines were added which
included lobular breast cancer, colon cancer or signet ring cell colon
cancer as a criteria for genetic testing. Isolated individuals with the
11
diagnosis of diffuse gastric cancer prior to the age of 45, as well as
individuals with diffuse gastric cancer and lobular breast cancer without
any family history, were also included as criteria for CDH1 mutation
testing.
Prophylactic gastrectomy:
The New Zealand HDGC Group provided recommendations for
both screening and prophylactic gastrectomy. It recommended that patients
under 14 years need not be tested for CDH1 mutations, while those over 16
years should be tested. Prophylactic gastrectomy was not recommended for
patients aged less than 16 years and delaying prophylactic gastrectomy
beyond  30  years  of  age  was  proposed  to  carry  a  significant  risk  for
cancer.13
Outcome after prophylactic gastrectomy
In the young and healthy population, prophylactic gastrectomy was
associated with up to 2% mortality and up to 20% major acute morbidity
and 100% long-term morbidity. Hence, IGCLC recommended that
gastrectomy for HDGC should be done in centers performing at least 25
gastrectomies per year with a mortality of less than 5%.
12
Timing of prophylactic gastrectomy:
The New Zealand HDGC group has recommended doing the
procedure before 30 years of age. The Stanford group recommended
prophylactic gastrectomy 5 years earlier than the age at which the youngest
family member developed clinically apparent diffuse gastric cancer.
Importance of Total Gastrectomy:
The IGCLC emphasized the importance of prophylactic total
gastrectomy against subtotal gastrectomy and pathologically identifying
both the duodenal and esophageal mucosa in the surgical specimen. Also,
there can be multiple foci of malignant cells distributed throughout the
specimen. Therefore, leaving a residual stomach further exposes the at-risk
patient to the development of gastric cancer.
Familial Adenomatous Polyposis:
Approximately 85% of patients with familial adenomatous polyposis
have fundic gland polyps, and over 50% of them contain a somatic
adenomatous polyposis coli mutation and up to 40% of these having some
type of dysplasia which places these patients at risk of developing gastric
cancer. These polyps, along with duodenal polyps, need upper
gastrointestinal surveillance for malignant change.
13
Li-Fraumeni syndrome:
This is an autosomal dominant disorder caused by a mutation in the
p53, tumor suppressor gene. These patients are at risk for many cancers
including gastric cancer.
Lynch Syndrome:
Hereditary nonpolyposis colorectal cancer, or the Lynch syndrome,
which is responsible for 2% to 3% of all colon and rectal cancers, is
associated with microsatellite instability. This is also associated with an
increased risk of gastric and ovarian cancers.
Other Risk Factors:
Pernicious anemia:
These patients are at increased risk for developing gastric cancer.
The defining feature of this condition is Achlorhydria and it occurs when
the chief and parietal cells are destroyed by an autoimmune reaction. The
mucosa becomes atrophic and develops intestinal metaplasia. The patient
with pernicious anemia has a relative risk of up to 5.6 for developing
gastric cancer compared to the general population.
14
Polyps:
Adenomatous polyps carry a definite risk of malignancy in the
polyp. Mucosal atypia is frequently seen and progression to carcinoma in
situ has been observed. In approximately 10% to 20%, carcinoma develops
in the polyp and the risk increases with increasing size of the polyp.
Pedunculated polyps can be removed endoscopically and is sufficient if the
polyp is completely removed and there are no foci of invasive cancer.
Operative excision is warranted for a polyp more than 2 cms, sessile polyp
or a polyp with a proven focus of invasive carcinoma.
Fundic gland polyps are benign lesions that result from glandular
hyperplasia and decreased luminal flow. They are associated with proton
pump inhibitor use and occur in up to a third of patients by one year of
usage. But, dysplasia has only been described as individual case reports in
these polyps. These do not require excision, surveillance or cessation of
therapy.
Proton Pump Inhibitors (PPIs):
The PPIs usage has risen dramatically for patients with upper
gastrointestinal complaints. They are often the first-line treatment for
15
dyspepsia and reflux disease. The impact of PPIs on the incidence of
gastric cancer has not been fully elucidated.
PPIs block the hydrogen-potassium pump within the parietal cells,
thereby blocking all the acid secretion in stomach. As a result, patients on
PPIs develop hypergastrinemia, which reverses on PPI withdrawal. In
patients on long-term PPIs associated with H. pylori infection, the low-acid
environment allows the bacteria to colonize, leading to corpus gastritis.
Up to a third of patients with corpus gastritis develop atrophic
gastritis. This atrophic gastritis quickly resolves after eradication of H.
pylori. Currently, there is no study demonstrating the association of
atrophic gastritis in this subset of patients with an increased risk of cancer.
However, atrophic gastritis in general, is considered a major risk factor for
the development of gastric cancer. Hence, in patients with persistent
symptoms after initiation of therapy or who require long-term therapy,
surveillance and eradication of H. pylori is warranted. 8
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MECHANISMS OF MALIGNANT TRANSFORMATION IN
GASTRIC CANCER
Several molecular pathways interact in a complex way to ultimately
produce the cancer. The most common and the most well studied pathways
include the chromosomal instability, microsatellite instability and germline
E-cadherin mutation. These pathways lead to oncogenes activation, tumor
suppressor genes inactivation, telomerase reactivation, reduction of cellular
adhesion, defective regulators of growth regulators and regulator genes of
cell cycle and apoptotic genes.
Chromosomal Instability (CIN)
The commonest chromosomal abnormality in stomach cancer is the
chromosomal instability. Conspicuous chromosomal malformation with
addition or deletion of complete chromosome or part of a chromosome is
typical of CIN. Also, translocations and chromosomal amplifications are
common. The above abnormalities can influence the oncogenes, growth
regulators, tumour suppressor genes, DNA repair genes and cell cycle
checkpoint control genes. CIN in sporadic stomach cancers is very
common and is present in up to 80% of GI cancers. 12
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Various alterations in the chromosomal numbers have been
described and they have been linked to various factors like the tumor
differentiation, invasion, lymph node spread and distant metastasis.
Loss of heterozygosity also represents the chromosomal instability.
Evidence has shown that the degree of chromosomal loss is of clinical
course and outcome. Studies have shown that, high-level LOH is
associated with intestinal or mixed type of gastric cancers and low-level
LOH is associated with diffuse growth pattern. LOH is associated with
cancer advancement and conversion LOH-H from LOH-I indicate tumor
progression.
The genetic mechanisms of CIN are largely unknown.
Mechanisms of chromosomal alterations include
1. Chromosome segregation defects
2. Defective DNA repair
3. Defects in cell cycle regulators
4. Dysfunction of telomeres
In genetically vulnerable patients, certain mutagens like H.pylori,
tobacco and nitrites affect the normal chromosomal stability. They also
18
increase the risk of gastric cancer by oxidant free radical mediated tissue
damage.
Chromosome Segregation Dysfunction
Segregation is a fundamental process in all cells with frequent
mitoses including the mucosal cells of the stomach wall. When the
regulatory systems controlling these actions fail, the resultant cells will
either have errors in DNA or errors in the spindle. The cells will
consequently transmit these mutations or have an abnormal chromosomal
number.
Mechanisms for CIN development due to segregation dysfunction:
1.  Expression defects
2.  Genetic defects in segregation
3.  Carcinogens activity on individuals with susceptible genetic
background.
Defective DNA Damage Response
Gastric wall mucosal cells are continuously under the influence of
cellular and intraluminal carcinogens. These tumorogenic factors cause
damage in the DNA by various pathways.
19
The normal DNA repair systems are as follows:
1. Nucleotide excision for in vivo or oxidative defects
2. Adduct restoration by excising the nucleotide
3. Mismatch restoration
4. Slippage or recombination for restoring breaks in double-stranded
DNA.
When the above mechanisms fail, CIN and genomic aberrations
occur resulting in malignancy.
 Helicobacter-pylori induced chromosomal instability
H.pylori induces double stranded breaks in the DNA thereby leading
to chromosomal instability.
Helicobacter pylori infection initiates a chronic inflammatory trigger
that may lead to carcinogenesis by the following mechanisms:
1. Rapid cell division and mitoses
2. Accelerated mutagenesis
3. Free radicals induced damage
4. Negative regulation of repair mechanisms
20
The immune cells at the inflammatory area produce oxygen free
radicals and reactive nitrogen radicals play an important role in H.pylori
associated damage to the DNA. The DNA changes include cross linking of
the DNA, single stranded DNA breaks, direct mutation in p53 gene, and
inhibition of apoptosis by nitrosylation of caspases, protein damage by
nitrosylation, and promotion of angiogenesis. The genetic makeup of an
individual has a significant part in modulating the above events.
Microsatellite Instability (MSI)
Microsatellite Instability (MSI) is also commonly recognized in
gastric cancers. MSI is a classical chromosomal feature of hereditary
stomach cancer, developing with Lynch syndrome and in up to 50% of
sporadic cancers.
MSI patients have a higher rate of defects in replication. MMR
genes usually identify and restore the defects. Abnormalities in MMR
genes, especially MLH1/MSH2 causes tumor suppressor gene inactivation
and LOH, thereby leading to cancer. 5
Defective mismatch repair can occur by the following ways
1. Inactive MMR genes due to mutation
2. Inactive MMR genes due to epigenetic mechanisms
21
In stomach cancer, defective mismatch repair is typically caused by
CpG island methylator pathway (CIMP).
Genes that are frequently affected because of defective mismatch
repair include cellular cycle genes and apoptotic genes and that are
involved in genomic integrity maintenance. These alterations further
promote genetic instability and enhance the carcinogenesis.
Mutation in E-cadherin gene (CDH1)
E-cadherin mutations are well documented in younger age stomach
tumors and in hereditary tumors. Somatic inactivation of this gene
manifests as aggressive tumor with poor prognosis.
22
IMPORTANT GENE ABNORMALITIES
Members of Tyrosine kinase family
Tyrosine kinase family genes including HER2/neu, K-sam and c-
met when amplified indicate stomach cancer advancement. 7
The c-met oncogene, a member of the hepatocyte growth factor
receptor family is more commonly involved in diffuse cancers.  The c-met
oncogene mutation is associated with advanced tumor stage and poor
outlook.
The oncogene K-sam belongs to the fibroblast growth factor
receptor family, and is commonly involved in diffuse cancers. Increased
expression is seen with 30% of diffuse stomach cancers. The K-sam
oncogene mutation is associated with poor outlook.
The HER2/neu glycoprotein is homologous to the epidermal growth
factor receptor. Studies demonstrate that increased expression is
preferentially found in intestinal type cancers and serve as an indicator for
nodal metastasis and invasion. Increased expression of HER2/neu protein
is up to 30% of stomach malignancy. Also, increased expression of
HER2/neu predicts a poor survival.
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RUNX3
RUNX3, is a member of the runt domain-containing family of
transcription factors and is expressed in only 40% of gastric cancers. This
factor affects cell growth, angiogenesis and apoptosis by having a negative
influence on the vascular endothelial growth factor (VEGF) and positive
influence on the levels of p21. Low levels of RUNX3 are associated with
poor survival.
Vascular Endothelial Growth Factor (VEGF)
The pro-angiogenic VEGF is commonly seen in increased levels in
stomach cancer. P53 gene has a negative influence on the VEGF in normal
conditions and may be a factor in the increased level of VEGF. VEGF
levels correlate with nodal spread as well as hepatic spread. Increased
levels are associated with a poor outlook.
Cyclooxygenase 2(COX2)
This is a key enzyme in prostaglandins production in the stomach
mucosa and has a part in the stomach cancer pathogenesis. Increased
expression of COX2 is associated with lymphatic spread, poor cellular
differentiation and invasion and hence signifies a poor outlook.
24
Osteonectin
Osteonectin belongs to the group of matrix cellular proteins. They
modulate cellular and matrix relations and influence cellular performance
without taking part in the extracellular matrix structure. Overexpression of
osteonectin correlates with distant metastasis and poor prognosis.
P53
P53 has a basic role in cellular growth and differentiation. Genetic
mutations and loss of heterozygosity are the common factors behind P53
gene abnormality. P53 abnormalities are seen in well differentiated
stomach tumors in up to 35% of cancers. P53 abnormalities are not seen in
early stage diffuse type tumors and tumors in young patients. They are
found in increased levels in early stage intestinal type tumors and in later
stages of the disease.
P21
The p21 protein is a cyclin dependant kinase inhibitor (CDK I)
mediating the cell cycle regulatory function of p53. Survival of gastric
cancer patients with p21-positive tumors is significantly longer than p21-
negative tumors. The expression of p21 assessed in combination with p53
status contributes to predict the clinical outcome in gastric cancer patients.
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p27
P27 is another cyclin-dependent inhibitor, which controls the
transition from G1 to S in the cell cycle. Reduced expression of p27 is seen
in approximately 45% of gastric cancers. Tumors with a low expression of
p27 protein are poorly differentiated and present at an advanced stage. P27
has also been analyzed in combination with p21 and p53, as prognostic
markers.
BCL2
BCL2 is involved in the regulation of apoptosis. LOH of the BCL2 is
frequently observed in gastric cancer. BCL2 overexpression reduces
cellular proliferative activity and correlates with a less aggressive behavior
of the tumor.
BAX
BAX gene encodes a protein of the BCL family members. Decreased
expression of BAX has been associated with poor differentiation, lymph
node metastasis and a shorter survival.
C-myc
C-myc gene encodes nuclear phosphoprotein that plays an important
role in cell cycle progression, cellular transformation and apoptosis. It acts
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as a transcription factor that regulates transcription of target genes. The c-
myc protein is significantly enhanced in well-differentiated gastric cancers
and is associated with a poor prognosis. In gastric cancers, overexpression
of the cancerous inhibitor of protein phosphate 2A (CIP2A) stabilizes c-
myc. CIP2A overexpression is also associated with reduced overall
survival.
Cyclin E
Cyclin E overexpression is a marker of tumor aggressiveness and
correlates with invasiveness and proliferation. Reduced expression is
associated with invasion and metastasis both diffuse and intestinal type
gastric carcinomas.
APC
Inactivation of Adenomatous Polyposis Coli gene leads to activation
of the Wnt-frizzled-?-catenin signaling pathway and is frequently seen in
gastric carcinoma. LOH of APC gene occurs in approximately 25% of
intestinal type gastric carcinomas. Inactivation of APC gene leads to poor
differentiation and increased tumor invasiveness.
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MUC1
Mucins are high molecular weight glycoproteins that are major
components of the mucus and protect the gastric epithelium. Mucin 1
(MUC1) overexpression is linked to accelerated tumor invasion by the
impairment of E-cadherin and indicates a poor prognosis in gastric cancer.
Survival for gastric cancer patients with abnormal E-cadherin and MUC
positive expression is shorter than others.
ARIDI1A
ARIDI1A, the short form for AT-rich interactive domain 1A, are
mutated in 90% of patients with MSI, 70% of Epstein-Barr virus infected
patients and in 10% of microsatellite stable and non EBV infected patients.
ARIDI1A controls genetic expressions by attaching itself to the AT-
rich sequence of the DNA. It is involved in repair of the DNA and plays a
controlling part in cellular division. ARIDI1A abnormalities predict a
comparatively better outlook in high MSI and EBVpositive stomach
cancers. ARIDI1A loss indicates a large tumor, invasiveness, nodal spread
and poor outlook in MSS and EBV negative stomach tumors. ARIDI1A
abnormalities are also inversely related to the P53 gene mutations and
directly related with the PIK3CA genetic abnormalities..
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EGFR
EGFR, or ErbB1, is a member of the tyrosine kinases family
and functions as a transmembrane receptor.  It has an intracellular
cytoplasmic domain, a transmembrane portion and an extracellular binding
domain.  Binding of a ligand to the extracellular domain leads to tyrosine
kinase phosphorylation and activation. The primary intracellular pathways
that are activated following the phosphorylation of EGFR include:
1. Phosphoinositol-3-kinase (PI3K)/Akt pathway
2. RAS/mitogen activated protein kinase (MAPK) pathway.
The PI3K pathway is involved in apoptotic and survival
signalling. The RAS/MAPK pathway is involved in cancer cell
proliferation and gene transcription.
EGFR inhibitors
Two classes of EGFR inhibitors are available:
1. Monoclonal antibodies
2. Small molecule tyrosine kinase inhibitors.
Monoclonal antibodies include cetuximab and panitumumab. Small
molecule tyrosine kinase inhibitors include erlotinib and gefitinib.
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FGFR2
FGFR2 is another member of the tyrosine kinases family and
functions as a transmembrane receptor. It has an intracellular cytoplasmic
tyrosine kinase domain, a transmembrane hydrophobic segment and an
extracellular, three immunoglobulin-like domains. The extracellular
portion interacts with fibroblast growth factors, triggering a cascade of
downstream signals, which ultimately influence mitogenesis and cellular
differentiation. The FGFR signalling axis plays a very important role in
normal skeletal, organ and vascular development. Germline mutation of
the FGFR gene is implicated in a variety of congenital disorders. In gastric
cancer, FGFR2 amplification occurs more frequently in undifferentiated
and diffuse cancers.
Inhibition of FGFR signaling can result in anti-proliferative and pro-
apoptotic effects.
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Survival in Gastric Cancer Patients
The prognosis of gastric cancer varies enormously across the world,
remaining dismal in the west whereas it has become favourable in Japan.
The 5-year survival on an average is only 25% in the west. In contrast, the
5-year survival is around 60% in patients with gastric cancer in Japan.
The good prognosis of carcinoma stomach in Japan is the result of
aggressive screening strategy and detection of early stage cancers. The lack
of improvement in survival in other areas has been attributed to aggressive
and advanced stage gastric cancers. Hence, controlling the stage of the
disease and modifying the risk factors are the factors that will lead to
improved patient outcomes.
Prevention of Gastric Cancer
Gastric cancer prevention can be done by two strategies:
1. Primary Prevention
Helicobacter pylori eradication
Modifying other risk factors
2. Secondary Prevention
Screening
31
Targeted molecular therapies in Gastric Cancer
The prognosis of gastric cancer patients in Indian scenario is very
bleak. Primary and secondary prevention strategies are not viable on large
scale and effective treatment, once the disease has occurred is the only
practical way at present. As far as the treatment is concerned, vast majority
of our patients present at a late and very advanced stage and curative
surgery is not feasible for them. Effective chemotherapy is the only hope
for them.
The chemotherapy regimens at present are not uniformly effective
and the response is highly variable. Targeted molecular therapy can be of
great help in such patients. Also, the targeted therapies can be used in early
stage disease also as adjuvant therapy.
The candidate genes/pathways that are actively investigated for
molecular target therapy in gastric cancer includes 11
1. Epidermal growth factor (EGFR)
2. Vascular endothelial growth factor (VEGF)
3. P13K/AKT/mTOR pathway
4. Insulin-like growth factor receptor (IGFR)
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5. MET pathways
6. FGFR
Various target agents are under study and the agents that are most
promising and in phase III clinical trials include
1. EGFR inhibitors
2. VEGF inhibitors
EGFR (Epidermal Growth Factor Receptor) inhibitors
Trastuzumab
Trastuzumab is a targeted agent against HER2 (c-erbB2) proto-
oncogene that encodes a tyrosine kinase receptor. HER2 (c-erbB2) is
overexpressed in many cancers, including gastric cancers. The ToGA trial
compared trastuzumab with chemotherapy and chemotherapy alone in
HER2-positive advanced gastric cancer patients. The study demonstrated
that adding trastuzumab to conventional chemotherapy is superior in
patients with HER2- positive advanced gastric cancer than chemotherapy
alone.
Lapatinib is another HER2 targeted agent which inhibits both EGFR
and HER2. It is actively investigated for trastuzumab- resistant gastric
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VEGF (Vascular Endothelial Growth Factor) inhibitors
Bevacizumab
Bevacizumab is a humanized monoclonal antibody against VEGF.
Bevacizmab is proved effective in colorectal, renal and lung malignancy as
well as recurrent glioblastoma.
The phase III study, the AVAGAST trial evaluated bevacizumab
combined with chemotherapy and chemotherapy alone in unresectable
gastric cancers. There was improvement in progression free survival and
overall response rate in bevacizumab treated patients.
Sunitinib and Sorafenib
These are also tyrosine kinase inhibitors with multi target activity,
recently introduced against VEGF.
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AIM OF THE STUDY
To investigate the mRNA expression levels of EGFR, FGFR2 &
C-Myc genes in the gastric cancers and their clinical significance.
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MATERIALS AND METHODS
Study Centre
Department of Surgical Gastroenterology
Center of Excellence for Upper G.I Surgery
Madras Medical College &
Rajiv Gandhi Government General Hospital
Chennai – 3
&
Department of Genetics
Dr.ALM PG IBMS
University of Madras
Taramani, Chennai – 600113
Study Period
August 2010 to December 2012
Study Design
Genetic Analysis
Sample Size
25
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Inclusion Criteria
Patients who underwent Gastrectomy (Subtotal or Total) for
Carcinoma stomach
Exclusion Criteria
Patients with Locally advanced disease
Patients with Metastatic disease
Analysis Plan
Comparing the gene levels of the putative genes with the reference
gene
METHODOLOGY
The study was approved by the ethics committee of Madras Medical
College and Rajiv Gandhi Government General Hospital.  Twenty five
patients fulfilling the study criteria and willing to give written and
informed consent were recruited for the study.
Cancerous and paired normal mucosa was collected after informed
consent from patients who undergo surgical resection. The sample is then
taken for genetic analysis.
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The steps of genetic analysis can be summarized as follows:
Sample collection and Transport
The tumor as well as normal tissue specimens were collected from
the fresh gastrectomy (Total / Sub-total) specimen removed for curative
intent treatment of cancer stomach.
The tumor samples were collected in RNAlater®, a dedicated
solution to maintain RNA stable in the tissue when sample transport is
performed in between the hospital and laboratory. All the tumor samples
obtained from the patients were identified clinically and confirmed by
pathological biopsy report.
Amplified by PCR
Electrophoresis & Semi-quantitative Analysis (UV band method)
UV Spectro - photometric Quality Check
RNA isolation (TRI reagent method)
Paired Cancerous & Normal mucosa from 25 Patients
Converted to cDNA (By RT- PCR)
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Total RNA isolation
Total RNA was isolated using TRI® reagent method. 50 mg of tumor
and normal tissue were taken in separate tubes and homogenized with 1 ml
of TRIzol. After homogenization, the homogenate was transferred into
fresh tube and 200 µl of chloroform was added. The tubes were then,
vigorously shaken for 15 min and centrifuged at 12,000 rpm for 15 min at
4° C. After centrifugation the aqueous phase was transferred into fresh tube
and 500 µl of Isopropanol was added. Then the tubes were frozen at -80  o C
for 3 hours. Later the tubes were taken out and thawed over ice and
immediately centrifuged at 12,000 rpm for about 15 min at 4°C. The
supernatant was decanted and with the pellet 750 µl 75% Ethanol was
added. The sample tubes were centrifuged at 12,000 rpm for 15 min at 4°C.
After centrifugation, the supernatant was discarded and pellet was air dried
at room temperature. Then the pellet was resuspended in 50 µl of RNase-
free water and stored at -80° C for later usage.
UV Spectrophotometric quantification
After the isolation of RNA, 1 µl of RNA was used to analyze the
quality using the UV spectrophometer (Nanodrop, Thermo).The A260 and
A280 Values  were  obtained  .Based  upon  the  A260 /A280 value, samples
between 1.8 to 2.1 were chosen as RNA samples with good yield and free
from other impurities.
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cDNA Synthesis
Based upon the RNA quality samples were selected for the Reverse
transcriptase Polymerase chain reaction to convert the RNA into cDNA
molecules. 5 µg of RNA was taken from each sample and diluted with
DEPC treated water and Random haxamer (100 µM) for the final volume
12 µL. Then the mixture was kept at 65°C for 20 Minutes in PCR machine.
After incubation the tubes were transferred on ice. The Pre-PCR mix was
mixed with RT buffer (1X); DTT (0.01M), dNTP (0.5mM).Finally,
Superscript III (Invitrogen Inc, USA) reverse transcriptase enzyme (200U)
was added separately into each reaction tube. The Final Volume was
adjusted to 20.0 µL and the tubes were kept at 50° C for 90 Minutes in PCR
machine. The reaction cycle was programmed as follows:  70°C for 15
Minutes then 4°C for 15 Minutes. After the completion of PCR, reaction
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the tubes were stored at -20°C. Then, 1:24 dilution was prepared with PCR
grade water for downstream application.
PCR using cDNA template
Polymerase chain reaction (PCR) methodology was standardized
using the laboratory working protocols. The concentration of reagents and
enzymes are given as below:
Reagents Stock Final
Per 10
?L Rxn
Volume
Required
??L)
Total
No.Rxn
(X=?)
Template
DNA
100ng/?
L * * 1 9
Taq Pol U
??L 5 * 0.25U 0.05 0.45
10 X PCR
Buffer 10 1 10 1 9
MgCl2 mM 25 2.5 10 1 9
dNTP ?M 2500 100 10 0.4 3.6
F Primer nM 2000 80 10 0.4 3.6
R Primer nM 2000 80 10 0.4 3.6
DD.H2O * * 10 5.75 51.75
Master Mix 81
For 10  ?L Rxn 9
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All PCR primers were designed using bioinformatic tools available
in the internet. The annealing temperature of the primers was normalized
to 60°C.The sequences of oligos have been given below:
EGFR: Forward 5'-AGGGACTGCGTCTCTTGCCG-3'
EGFR: Reverse 5'- CCTGGCCCAGTGCATCCGTAG -3'
FGFR2: Forward 5'- AGCGGCTGTACTGCAAAAACGG -3'
FGFR2: Reverse 5'- AGCCAGGTAACGGTTAGCACAC -3'
c-Myc: Forward 5'- AGCGAATAGGGGGCTTCGCC -3'
c-Myc: Reverse 5'- GGGAGGCTGCTGGTTTTCCAC -3'
GAPDH: Forward 5’-TTCGACAGTCAGCCGCATCTTCTT-3’
GAPDH: Reverse 5’-CAGGCGCCCAATACGACCAAATC-3’
The amplification of cDNA was carried out in ABI GeneAmp 9700
thermal cycler. The reaction condition has been given as below:
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The PCR amplicons obtained from different gene targets namely
GAPDH and EGFR, FGFR2 and C-Myc. 10 µl of PCR product was mixed
2 µl of 6X gel loading dye. The samples were resolved in 1 % agarose
TAE gel containing Ethidium bromide. The Electrophoresis was carried
out at 100V for 20 Minutes. After the visual observation of loading dye
migration, the gels were UV photographed with the aid of UV-
transilluminator. Finally the photographs were saved for further gel
quantification analysis.
Semi quantification Gene expression level
Amplified PCR products were resolved in 1 % TAE agarose gel
stained with Ethidium Bromide. The gel image was captured in UV-
Transilluminator and subsequently the band intensity of the PCR products
were calculated using UVI band software available with gel imaging
system. The band intensity of reference GAPDH was compared with band
images of EGFR, FGFR2 and C-Myc. The comparative signals were then
tabulated to generate a bar diagram summarizing the gene expression
pattern.
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RESULTS
The analysis demonstrates that the genes EGFR, FGFR and C-Myc
are highly expressed in tumor mucosa when compared with the normal
mucosa.
We found that C-Myc and EGFR are expressed more abundantly
when compared to FGFR2.
The results of the study are pictorially depicted as follows:
Total RNA isolated from Gastric tumor Mucosa
T1 T2 T3 T4
28 S
18 S
5 & 5.8 S
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Agarose Gel Electrophoregram of PCR product of GAPDH mRNA
Sample Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Tumor 98.73 92.023 94.18 96.2 97.66 98.4 93.19 99.54 98 93.98 94.67 94.29 97.9 96.9 97.32
Sample Number 16 17 18 19 20 21 22 23 24 25
Tumor 98.642 94.83 92.96 95.8 97.3 96.74 96.82 98.34 96.39 98.47
100bp T1 T2 T3 T4
327 bp
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GAPDH mRNA Expression Level
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Agarose Gel Electrophoregram of PCR product - EGFR mRNA
Sample Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Tumor 118.56 102.06 104.66 117.3 92.5 99.2 108.65 114.58 125.4 148.71 152.51 76.96 106.036 112.936 120.736
Sample Number 16 17 18 19 20 21 22 23 24 25
Tumor 120.42 141.08 131.02 126.7 128.23 102.72 83.16 114.8 111.21 134.23
100bp T1 T2 T3 T4
335 bp
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EGFR mRNA Expression Level
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Agarose Gel Electrophoregram of PCR product - FGFR2 mRNA
Sample Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Tumor 89.73 78.93 83.8 75.2 132.2 125.07 127.87 119.57 111.27 102.97 94.67 76.37 73.37 50.07 98.37
Sample Number 16 17 18 19 20 21 22 23 24 25
Tumor 90.07 109.07 124.37 116.07 150.37 99.47 91.17 82.87 104.17 107.77
100bp T1 T2 T3 T4
164 bp
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FGFR2 mRNA Expression Level
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Agarose Gel Electrophoregram of PCR product - c- Myc mRNA
Sample Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Tumor 132.73 133.47 138.21 128.37 105.91 111.65 98.945 118.685 103.72 112.854 113.594 119.914 122.714 130.454 121.714
Sample Number 16 17 18 19 20 21 22 23 24 25
Tumor 109.674 128.414 93.684 111.504 112.244 112.984 113.724 114.464 115.204 115.944
100bp T1 T2 T3 T4
228 bp
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C-Myc mRNA Expression Level
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DISCUSSION
Stomach cancer is a major age associated cancer. Surgical therapy is
the most promising treatment modality for the management.
Identification of early stage cancers and recurrences by unique
molecular signature is possible in these tumors. A novel non-invasive
method towards the early diagnosis of Gastric cancer remains a global hunt
for decades.
Levels of EGFR, FGFR2 and C-Myc genes are frequently
overexpressed in glandular epithelial cancers, including Gastric cancer.
The mRNA level of tumor specific genes EGFR, FGFR2 & C-Myc is often
associated with gastric carcinogenesis by triggering a cascade of molecular
events.
This is the first study of expression of the above three genes in
Indian patients. This study analyzes the mRNA expression levels of EGFR,
FGFR2 & C-Myc genes in the gastric cancers and their clinical
significance. This study was a prospective genetic analysis study done
during the period August 2010 to December 2012.
This is a pilot study and hence, only 25 patients were recruited for
genetic analysis after written informed consent and ethical committee
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approval. The positive result of this study has prompted us to extend the
study with large sample size and advanced experimental set up to prove the
usefulness of these molecular markers in the gastric cancer patient
management.
Also, further correlation of the levels of these mRNAs with clinic-
pathological features is planned as an extension of this study.
This  study  is  based  on  the  study  by  HK  Kim  et  al, 14 from  the
National Cancer Institute, Bethesda, MD, USA. HK Kim et al analysed the
transcriptional profiles of stomach cancer patients to assess the effects of
chemotherapy (fluorouracil and cisplatin). They concluded that combined
expression of C-MYC, FGFR2 and EGFR in metastatic gastric cancer is
predictive of poor survival in chemotherapy treated patients.
Based on the above study, we analysed the above three gene
signature in our patients with cancer of stomach cancer who underwent
gastrectomy with curative intent.curative gastrectomy.  The reference gene
in our study was also GAPDH (Glyceraldehyde-3-phosphate
dehydrogenase), one of the most common housekeeping genes used to
normalize gene expression data in genetic studies.
Our results show that the three gene signature (EGFR, FGFR2 & C-
Myc) is significantly overexpressed in the gastric cancers even in the early
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stage of the disease. This is the only study in the world literature,
demonstrating the usefulness of this gene signature in early stage gastric
cancers.
This opens up a whole new window of exciting possibilities directed
against these genes in early stage gastric cancers including
1. Diagnosis of early cancers
2. Targeted molecular therapy
3. Predicting the survival after surgery
4. Predicting tumor response to chemotherapeutic drugs
But, our study results need confirmation in a larger clinical trial with
adequate sample size to prove the role of this gene signature conclusively.
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REVIEW OF LITERATURE
The  study  by  HK Kim et  al, 14 from the National Cancer Institute,
Bethesda, MD, USA is the only other literature available regarding this
three gene signature.
They have studied the transcriptional profiles of gastric cancer
patients to predict the usefulness of chemotherapy (fluorouracil and
cisplatin) in patients with metastatic disease.
The study was done at the National Cancer Center Hospital, Korea
after Institutional Ethical Committee approval.
Their inclusion criteria included:
1. Age: More than 18 years
2. Biopsy proved adenocarcinoma of stomach
3. Distant metastasis – Clinically demonstrated
4. No other malignancy
5. No chemotherapy history before
6. Normal organ functions
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Their exclusion criteria included:
1. Patients who didn’t  complete chemotherapy
The primary endpoint of their study was overall survival. The
training set for expression profiling were the patients who underwent
chemotherapy – a total of 96 patients. Validation and training samples
underwent the same tissue procurement and processing.
Chemotherapy was continued until the patients had severe toxicities
or the disease was progressive inspite of chemotherapy.
Genetic analysis was done using transcriptional profiling and
Comparative Genomic Hybridization (CGH). Transcriptional profiling
identified 917 genes that were correlated with poor patient survival after
chemotherapy. Making use of the genes identified within the genomic
amplicons, a risk predictor for survival was constructed.
The three genes (C-MYC, EGFR and FGFR2) when expressed
together, independently predicted a poor overall survival. Thus, when
expressed together, C-MYC, EGFR and FGFR2 were predictors of poor
survival in metastatic stomach cancer cases treated with chemotherapy.
These three genes did not predict the prognosis and only predicted
the chemotherapy response.
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CONCLUSION
Our results show that the three gene signature (EGFR, FGFR2 & C-
Myc) is significantly overexpressed in the gastric cancers and this opens up
exciting possibilities in
1. Diagnosis of early gastric cancers
2. Targeted molecular therapy
3. Predicting the survival after surgery
4. Predicting tumor response to chemotherapeutic drugs
But, our study results need confirmation in a larger clinical trial with
adequate sample size to prove the role of this gene signature conclusively.
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CASE RECORD FORM
Name: Age / Sex: IP NO:
Occupation: Address:
Contact Number:
LAB ID:
GENETIC ANALYSIS RESULT:
HISTOPATHOLOGY REPORT:
Type of Malignancy:
Grade:
PATIENT DETAILS
Lab ID Gender/Age Type of Malignancy Pathological Status
GC001 F/52 Adenocarcinoma Poorly Differentiated
GC002 F/35 Adenocarcinoma Poorly Differentiated
GC003 M/43 Adenocarcinoma Poorly Differentiated
GC004 M/50 Adenocarcinoma Poorly Differentiated
GC005 M/62 Adenocarcinoma Poorly Differentiated
GC006 F/62 Adenocarcinoma Poorly Differentiated
GC007 M/48 Adenocarcinoma Poorly Differentiated
GC008 F/28 Adenocarcinoma Poorly Differentiated
GC009 F/50 Adenocarcinoma Poorly Differentiated
GC010 M/73 Adenocarcinoma Moderately Differentiated
GC011 M/80 Adenocarcinoma Poorly Differentiated
GC012 M/60 Adenocarcinoma Moderately Differentiated
GC013 M/60 Adenocarcinoma Moderately Differentiated
GC014 M/35 Adenocarcinoma Poorly Differentiated
GC015 M/50 Adenocarcinoma Moderately differentiated
GC016 F/65 Adenocarcinoma Poorly Differentiated
GC017 M/40 Adenocarcinoma Well  Differentiated
GC018 M/60 Adenocarcinoma Poorly Differentiated
GC019 M/45 Adenocarcinoma Poorly Differentiated
GC020 F/45 Adenocarcinoma Moderately differentiated
GC021 M/65 Adenocarcinoma Poorly Differentiated
GC022 M/60 Adenocarcinoma Moderately differentiated
GC023 M/48 Adenocarcinoma Poorly Differentiated
GC024 M/62 Adenocarcinoma Moderately differentiated
GC025 M/67 Adenocarcinoma Well  Differentiated
INFORMED CONSENT FORM – ENGLISH
Title of the study – Analysis of Three gene signature in Gastric
Cancer Patients
Name of the participant: __________________________________________
Name of the Principal/Co-Investigator: SATHEESH KUMAR M
Name of the Institution: MADRAS MEDICAL COLLEGE AND RAJIV
GANDHI GOVERNMENT GENERAL
HOSPITAL
Name and address of the sponsor / agency (ies), if any: Nil
I,_________________(name of participant), have read the information in this
form (or it has been read to me).
I was free to ask any questions and they have been answered. I am over 18 years
of age and, exercising my free power of choice, hereby give my consent to be
included as a participant in “Analysis of Three gene signature in Gastric
Cancer Patients”
1. I have read and understood this consent form and the information
provided to me.
2. I have had the consent document explained to me.
3. I have been explained about the nature of the study.
4. I have been explained about my rights and responsibilities by the
investigator.
5. I have informed the investigator of all the treatments I am taking or
have taken in the past ______ months including any native
(alternative) treatments.
6. I hereby give permission to the investigators to release the information
obtained from me as result of participation in this study to the
sponsors, regulatory authorities, Government agencies, and ethics
committee. I understand that they may inspect my original records.
7. I understand that my identity will be kept confidential if my data are
publicly presented.
8. I have had my questions answered to my satisfaction.
9. I consent voluntarily to participate as a participant in this research
study.
        I am aware, that if I have any questions during this study, I should contact
the investigators. By signing this consent from, I attest that the information given
in this document has been clearly explained to me and understood by me. I will
be given a copy of this consent document.
Name and signature / thumb impression of the participant:
(Name) __________________________(Signature)___________________
Date:
Name and signature of the Investigator:
(Name) _________________________(Signature)____________________
Date:
INFORMED CONSENT FORM – TAMIL
INFORMATION TO PARTICIPANTS
Title: ANALYSIS OF THREE GENE SIGNATURE IN GASTRIC
CANCER PATIENTS
Principal Investigator/Co-Investigator: SATHEESH KUMAR M
Name of Participant: _____________________________
You are invited to take part in this research.The information in this
document is meant to help you decide whether or not to take part. Please
feel free to ask if you have any queries or concerns.
What is the purpose of research?
Stomach cancer is a major age associated cancer.
Surgical therapy is the most promising treatment modality for the
management. Identification of early stage cancers and recurrences by
unique molecular signature is possible in these tumors.
A novel non-invasive method towards the early diagnosis of Gastric
cancer remains a global hunt for decades.
Levels of three genes, EGFR, FGFR and C-Myc genes are
frequently over expressed in glandular epithelial cancers, including Gastric
cancer.
We want to investigate the mRNA expression levels of EGFR,
FGFR2 & C-Myc genes in the gastric cancers and their clinical
significance.
We have obtained permission from the Institutional Ethics
Committee.
Study Procedures
The study involves Cancerous and paired normal mucosa is
collected after informed consent from patients who undergo surgical
resection for gastric cancer. The sample is then taken for genetic analysis.
Possible risks to you
There is absolutely no risk to you from the study procedure per se as
the mucosal samples are collected only from the surgically resected
specimen.
Possible benefits to you
This study will not benefit you as this is a genetic research study and
not recommended in clinical practice.
Possible benefits to other people
The results of the research may provide benefits to the society in
terms of advancement of medical knowledge and/or therapeutic benefit to
future patients.
Confidentiality of the information obtained from you
You have the right to confidentiality regarding the privacy of your
medical information (personal details, results of physical examinations,
investigations, and your medical history). By signing this document, you
will be allowing the research team investigators, other study personnel,
Institutional Ethics Committee and any person or agency required by law
to view your data, if required.
The information from this study, if published in scientific journals or
presented at scientific meetings, will not reveal your identity.
How will your decision to not participate in the study affect you
Your decision not to participate in this research study will not affect
your medical care or your relationship with the investigator or the
institution. You will be taken care of  and you will not loose any benefits
to which you are entitled.
Can you decide to stop participating in the study once you start
The participation in this research is purely voluntary and you have
the right to withdraw from this study at any time during the course of the
study without giving any reasons.
Signature of Investigator Signature of Participant
Date:                                                                Date:
ETHICAL COMMITTEE APPROVAL LETTER


